 NASDQ: IMRN, an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a new research agreement with the Naval Medical Research Center NMRC, Silver Spring, MD, USA. The focus of this new agreement will be to develop a combined Campylobacter and enterotoxigenic E. coli ETEC-specific anti-microbial preventative for clinical evaluation. 